Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy maintains a Buy rating on MetaVia (MTVA) with an $8 price target, citing promising clinical data for its next-gen obesity drug DA-1726 and upcoming catalysts. H.C. Wainwright also issued a Buy rating with a $20 target. Despite the bullish analyst sentiment, MTVA stock has dropped 78.79% over the past six months.
Maxim Group analyst Jason McCarthy has maintained their bullish stance on MTVA stock, giving a Buy rating yesterday.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Jason McCarthy has given his Buy rating due to a combination of factors, including the strong clinical profile emerging for DA-1726 and clear upcoming catalysts. He highlights that MetaVia’s dual GLP-1/glucagon agonist has already shown meaningful weight loss, waist circumference reduction, and favorable metabolic effects in early-stage trials, with Part 3 now advancing in obese patients over a longer 16-week period.
He also points out that DA-1726 has attracted attention as a next-generation obesity therapy, being mentioned alongside leading players in the GLP-1 space, which underscores its strategic positioning. With top-line data from the titration phase expected in 4Q26 and the mechanism of action supporting both efficacy and tolerability, McCarthy maintains conviction in MetaVia’s upside potential and keeps his price target unchanged at $8.
In another report released yesterday, H.C. Wainwright also assigned a Buy rating to the stock with a $20.00 price target.
MTVA’s price has also changed dramatically for the past six months – from $8.155 to $1.730, which is a -78.79% drop .